REGENXBIO shares fell nearly 20% after the company priced a $100 million public offering of common stock and pre-funded warrants. The sizable equity issuance signals potential dilution, contributing to a negative near-term reaction in the stock.
REGENXBIO shares fell nearly 20% after the company priced a $100 million public offering of common stock and pre-funded warrants. The sizable equity issuance signals potential dilution, contributing to a negative near-term reaction in the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
